Vizgen is a biotech company that develops solutions for next-generation spatially resolved, single-cell transcriptomics.
Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 3, 2022 | Series C | $85.20M | 7 | ARCH Venture Partners Blue Water Life Science Advisors | — | Detail |
Apr 7, 2021 | Series B | $37M | 6 | Northpond Ventures Novalis LifeSciences | — | Detail |
Jan 30, 2020 | Series A | $14M | 2 | ARCH Venture Partners Northpond Ventures | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Dec 8, 2022
Metagood
|
Pre-seed | $5M | Cryptocurrency | — |
Jul 14, 2022
Trend
|
Pre-seed | $3M | Advertising Platforms | — |
Mar 4, 2022
Block Tackle
|
Seed | $5M | Blockchain | — |
Jan 11, 2022
Lootex
|
Seed | $9M | Blockchain | — |
Jan 5, 2022
CryptoSlam
|
Seed | $9M | Blockchain | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | Yes | Series C |
Blue Water Life Science Advisors | Yes | Series C |
David Walt | — | Series C |
Northpond Ventures | — | Series C |
Novalis LifeSciences | — | Series C |
Sofina | — | Series C |
Tao Capital Partners | — | Series C |
David R. Walt | — | Series B |
Pura Vida Investments | — | Series B |